Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 07 03:50PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.68 Insider Own2.80% Shs Outstand14.62M Perf Week2.15%
Market Cap327.64M Forward P/E- EPS next Y-0.32 Insider Trans0.00% Shs Float14.23M Perf Month6.62%
Income-24.57M PEG- EPS next Q-0.23 Inst Own89.29% Short Float / Ratio3.44% / 2.54 Perf Quarter29.29%
Sales163.31M P/S2.01 EPS this Y10.46% Inst Trans-0.72% Short Interest0.49M Perf Half Y-16.52%
Book/sh18.48 P/B1.21 EPS next Y64.60% ROA-7.27% Target Price27.33 Perf Year-27.38%
Cash/sh4.83 P/C4.64 EPS next 5Y10.00% ROE-8.85% 52W Range16.54 - 32.33 Perf YTD-24.39%
Dividend- P/FCF- EPS past 5Y- ROI-8.25% 52W High-30.78% Beta0.76
Dividend %- Quick Ratio4.03 Sales past 5Y6.89% Gross Margin61.78% 52W Low35.31% ATR0.80
Employees345 Current Ratio5.59 Sales Q/Q2.98% Oper. Margin-18.69% RSI (14)61.96 Volatility3.59% 3.61%
OptionableYes Debt/Eq0.11 EPS Q/Q-57.15% Profit Margin-15.05% Rel Volume0.26 Prev Close21.97
ShortableYes LT Debt/Eq0.10 EarningsNov 02 AMC Payout- Avg Volume192.35K Price22.38
Recom1.67 SMA205.11% SMA5011.82% SMA200-4.97% Volume48,232 Change1.87%
Date Action Analyst Rating Change Price Target Change
Aug-14-23Upgrade Barrington Research Mkt Perform → Outperform $24
Mar-07-23Downgrade Barrington Research Outperform → Mkt Perform
Nov-09-22Upgrade Barrington Research Mkt Perform → Outperform $31
Oct-14-22Resumed Stephens Equal-Weight $26
Mar-09-22Downgrade Stephens Overweight → Equal-Weight $35
Mar-09-22Downgrade Barrington Research Outperform → Mkt Perform
Nov-16-21Initiated Stephens Overweight $55
Jul-16-21Initiated UBS Neutral $46
Dec-16-20Upgrade Barrington Research Mkt Perform → Outperform $43
May-08-20Downgrade Barrington Research Outperform → Mkt Perform
Nov-28-23 09:00AM
Nov-07-23 04:05PM
Nov-05-23 02:26PM
Nov-03-23 09:43AM
Nov-02-23 06:11PM
05:00PM Loading…
Oct-10-23 09:00AM
Oct-04-23 07:18AM
Oct-03-23 09:11AM
Sep-19-23 09:00AM
Sep-15-23 07:44PM
Sep-12-23 09:00AM
06:51PM Loading…
Sep-01-23 06:51PM
Aug-31-23 12:00PM
Aug-22-23 07:22AM
Aug-17-23 06:20PM
Aug-14-23 09:59AM
Aug-11-23 07:07AM
Aug-09-23 09:03AM
Aug-08-23 06:55PM
Aug-03-23 07:33PM
Jul-20-23 04:05PM
09:00AM Loading…
Jul-12-23 09:00AM
Jun-21-23 08:00PM
May-30-23 04:05PM
May-15-23 09:19AM
May-09-23 07:15PM
Apr-26-23 08:00PM
Apr-19-23 11:32AM
Apr-13-23 05:44PM
Apr-12-23 09:00AM
Apr-03-23 09:00AM
Mar-27-23 04:55PM
Mar-20-23 06:15PM
Mar-18-23 10:08AM
Mar-15-23 04:01PM
Mar-08-23 10:00AM
Mar-07-23 09:52AM
Mar-06-23 05:45PM
Feb-28-23 09:00AM
Feb-27-23 06:15PM
Feb-21-23 06:15PM
Feb-20-23 09:25AM
Feb-14-23 06:15PM
Feb-13-23 08:30AM
Feb-07-23 06:15PM
Jan-30-23 06:15PM
Jan-17-23 09:40AM
Jan-09-23 10:04AM
Dec-28-22 07:05AM
Nov-10-22 01:24PM
Nov-08-22 07:35PM
Nov-01-22 12:14PM
Oct-25-22 09:25AM
Oct-17-22 01:13PM
Oct-11-22 09:41AM
Sep-12-22 04:01PM
Aug-03-22 05:45PM
Jul-27-22 09:15AM
Jul-21-22 07:20AM
Jul-19-22 10:42AM
Jul-12-22 05:05PM
Jun-14-22 02:45PM
Jun-10-22 09:27AM
May-20-22 03:07PM
May-13-22 05:00PM
May-10-22 10:50AM
May-09-22 04:05PM
May-05-22 04:05PM
May-04-22 07:55AM
Apr-26-22 07:24AM
Apr-19-22 05:50AM
Apr-15-22 05:00PM
Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company's main focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and its products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika Therapeutics was founded in 1992 and is headquartered in Bedford, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nunes AnneSVP, Chief Operations OfficerOct 01Option Exercise0.002,49105,784Oct 03 04:31 PM
Levitz Michael LEVP, CFO, TreasurerAug 10Option Exercise0.003,859034,365Aug 11 04:30 PM
Blanchard Cheryl RPresident, CEO, DirectorApr 26Option Exercise0.0024,5750125,155Apr 28 04:30 PM
Blanchard Cheryl RPresident, CEO, DirectorMar 10Option Exercise0.0030,0600113,791Mar 14 04:46 PM
Colleran DavidEVP, General Counsel, Corp SecMar 10Option Exercise0.007,663022,538Mar 14 04:46 PM
Levitz Michael LEVP, CFO, TreasurerMar 10Option Exercise0.008,888032,447Mar 14 04:47 PM
Levitz Michael LEVP, CFO, TreasurerMar 09Option Exercise0.004,439024,862Mar 10 04:52 PM
Blanchard Cheryl RPresident, CEO, DirectorMar 09Option Exercise0.0014,419087,963Mar 10 04:51 PM
Colleran DavidEVP, General Counsel, Corp SecMar 09Option Exercise0.003,683015,956Mar 10 04:51 PM
Colleran DavidEVP, General Counsel, Corp SecMar 04Option Exercise0.002,500013,007Mar 07 04:34 PM